The introduction of intravenous fluid therapy provides no notable improvements in managing migraine headache pain but may have the possibility of getting a clinically relevant treatment effect in the future, findings of a randomized controlled trial published in the Journal of Annals of Emergency Medicine.

Patients received either saline solution at 10 mL/hour for 1 hour (control group) or 1 L of normal saline solution during 1 hour (fluid group). Before the fluid administration, all patients received intravenous diphenhydramine or prochlorperazine. Assessment of outcomes was done at one, two and 48 hours. The difference in the verbal pain rating between 0 and 60 minutes was considered as the primary outcome, and the rate of protocol completion, the effectiveness of blinding, and additional clinical endpoints were considered as the secondary outcomes.

Out of the total 50 participants, one withdrew from the analysis. Patients of the fluid group exhibited 4.5 mean improvements in 0- to 60-minute pain score as compared to the 4.9 of the control group. Further, only one patient correctly identified the group assignment. The approach to blinding and study protocol was effective and feasible. Further analysis is required to validate the efficacy of fluid administration for getting notable treatment effects.